Complex regional pain syndrome (CRPS) has been reported and studied in adults for many years. It is a less acknowledged disorder in children, probably due to underdiagnosis. The presentation and ...

BRC-002 is an oral botanically-derived cannabinoid agent expected to reduce the pain and comorbidities associated with CRPS. The FDA has granted Orphan Drug designation to BRC-002 (cannabidiol ...

Recent studies have highlighted how chronic pain conditions like back pain, fibromyalgia, and complex regional pain syndrome ...

"Sometimes with pain you actually need that in-patient whole multidisciplinary team ... Paul Vroegop said children who were treated for CRPS had "a 99 percent recovery rate".

Safety and efficacy are currently being assessed in investigator-initiated clinical trial. BRC is planning to commence enrollment for a Phase 2 trial by the end of 2025. CRPS is a debilitating ...

CRPS can present with a wide range of symptoms, but the hallmark is pain out of proportion to the inciting event. It usually occurs in the hands or feet, which are rich in nerve innervation, but ...